Atlas Trials

Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy

Clinical trial NCT01625741 · TERMINATED

Trial details

NCT number
NCT01625741
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Lymphocytic Leukemia
Start date
2012-07-01
Primary completion
2015-05-01
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.